Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
New study provides reassurance for men taking blood pressure and cholesterol modifying medications, reports the Canadian Journal of Cardiology.
In just four months, high-doses of vitamin D reduce arterial stiffness in young, overweight/obese, vitamin-deficient, but otherwise still healthy African-Americans, researchers say.
The U.S. Food and Drug Administration today approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive shock.
With the support of the FWF, an oncologist found a biomarker for breast cancer having a poor prognosis and developed two viable methods to detect it in tissue samples.
Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators.
Researchers have found a link between dysregulated tryptophan metabolism and abdominal aortic aneurysm, a life-threatening vascular disease, according to a new study led by Georgia State University.
Heart failure (HF) affects approximately 5.7 million adults in the United States according to the Centers for Disease Control and Prevention. If not properly managed, HF can lead to frequent hospitalizations.
An international team of researchers led by Johns Hopkins has shown that a topical gel made from a class of common blood pressure pills that block inflammation pathways speeds the healing of chronic skin wounds in mice and pigs.
Humana Inc. today announced results from a study that found a relationship between patient-reported, health-related quality of life and multiple objective measures of health in elderly Medicare Advantage patients with chronic conditions.
While the average American's high-salt diet has been linked to high blood pressure and cardiovascular disease, the truth is we couldn't live without this once scarce mineral.
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins.
Preeclampsia may permanently change the blood vessels of women who experience the condition during pregnancy, boosting their lifelong risk for cardiovascular disease, according to Penn State researchers.
University of Arizona researchers are collaborating on a Phase 2 trial to determine whether a particular peptide administered before and after coronary bypass surgery mitigates or even reverses cognitive deficits thought to be connected to the procedure.
Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line - LBCT Session at ESC Congress1 and published in the NEJM.
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.
Sixty years after Cleveland Clinic researchers first isolated the role of angiotensin II in controlling blood pressure, a new international study led by Cleveland Clinic researchers shows that the compound can safely improve blood pressure among critically ill patients who are experiencing life-threatening hypotension, or low blood pressure.
Shortness of breath is the No.1 complaint of people suffering from heart failure. Now a University of Guelph researcher has discovered its surprising cause - and an effective treatment - in a groundbreaking new study.
Scientists have determined unexpected characteristics of a key protein linked to blood pressure control and to nerve growth, pain control and heart tissue regeneration. The findings, published April 5 online in the journal Nature, opens doors to potential new therapies to control cardiovascular disease and pain.
Researchers hope to design a new generation of drugs against an array of deadly diseases. The task, however, is costly, arduous and often ineffective. One of the key challenges is understanding a particular class of proteins adorning cell surfaces, which are the targets of the majority of pharmaceutical drugs.
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.